Vladimir Cotarlan, MD
Advanced Heart Failure and Transplant Cardiology · Cincinnati, OHNPI 1124294442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Abbott at 48.6% of the total. Reporting peaked in 2023 at $796 and has fallen 70.4% since, to $236 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in OH, where the typical reported total is $4,421.
Across 35 payments — averaging $58.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$999
- E.r. Squibb & Sons, L.L.C.$417
- Impulse Dynamics (USA) Inc.$149
- Daxor Corporation$124
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
- Novartis$72
- plus $196 from 7 others
Across 16 payments — averaging $15,104 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$213K
- Amgen$28K
What the payments were for
- Food & beverage$2,057100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 10 | $999 |
| E.r. Squibb & Sons, L.L.C. | 7 | $417 |
| Impulse Dynamics (USA) Inc. | 1 | $149 |
| Daxor Corporation | 1 | $124 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Novartis | 4 | $72 |
| Atricure, Inc. | 3 | $71 |
| Boehringer Ingelheim | 2 | $38 |
| Johnson & Johnson | 2 | $23 |
| Endotronix, Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $19 |
| Cvrx, Inc. | 1 | $14 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$331
- OPTIMIZER$298
- CAMZYOS$297
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$291
- MitraClip System$160
- BVA-100$124
How this compares
$2,057 in reported general payments places this provider in the 25th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 68 | $98,625 |
| EliquisApixaban | 31 | $42,112 |
| JardianceEmpagliflozin | 16 | $22,618 |
| Mycophenolate Mofetil | 74 | $5,500 |
| Tacrolimus | 44 | $3,642 |
| Eplerenone | 16 | $2,065 |
| Cyclosporine ModifiedCyclosporine, Modified | 19 | $1,852 |
| Metoprolol Succinate | 87 | $1,667 |
| Atorvastatin Calcium | 51 | $454 |
| Potassium Chloride | 11 | $394 |
| Torsemide | 18 | $373 |
| Pantoprazole Sodium | 33 | $233 |
| Pravastatin Sodium | 34 | $224 |
| Valsartan | 18 | $222 |
| Spironolactone | 21 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $72 | $98,62568 claims |
| Boehringer IngelheimJardiance | $38 | $22,61816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Cincinnati
- Eugene ChungCincinnati$297K
- Ankit BhatiaCincinnati$141K
- Rachel GarciaCincinnati$104K
- Sateesh KesariCincinnati$101K
- Sitaramesh EmaniCincinnati$87K
- Gregory EgnaczykCincinnati$62K
- Santosh MenonCincinnati$30K
- Umama GorsiCincinnati$20K
- Stephanie DunlapCincinnati$9K
- Mahyar PourriahiCincinnati$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.